Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
- PMID: 38423591
- DOI: 10.1183/13993003.00233-2024
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
Conflict of interest statement
Conflict of interest: P-R. Burgel reports grants from Vertex Pharmaceuticals and GSK, consulting fees from AstraZeneca, Chiesi, GSK, Insmed, Vertex, Viatris and Zambon, and support for attending meetings and/or travel from AstraZeneca and Chiesi.
Comment on
-
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant.Eur Respir J. 2023 May 5;61(5):2202437. doi: 10.1183/13993003.02437-2022. Print 2023 May. Eur Respir J. 2023. PMID: 36796836